Covance Seeks Outside Investor For Expansion Of Biomanufacturing Business
Covance is seeking a third-party investment of several hundred million dollars to expand its commercial biomanufacturing business to meet growing demand.
You may also be interested in...
Novartis' cancellation of several outsourcing contracts with Parexel could result in a reduction of the contract research organization's workforce by 400-500 positions, Parexel said.
Covance will manufacture reteplase for U.S. and Canadian supply under a long-term contract. The fibrinolytic will be produced at Covance's new Research Triangle Park, N.C. facility. Previously Roche produced Retevase; Centocor purchased the product at the time of the 1997 Roche/Corange merger to prevent an antitrust conflict with Roche affiliate Genentech's Activase (alteplase)
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011